The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma.
PD-L1
TIRC7
biomarkers
cholangiocarcinoma
immune checkpoint inhibitors
immunotherapy
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Dec 2021
14 Dec 2021
Historique:
received:
25
11
2021
accepted:
07
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) is a heterogeneous malignancy with a dismal prognosis. Therapeutic options are largely limited to surgery and conventional chemotherapy offers limited benefit. As immunotherapy has proven highly effective in various cancer types, we have undertaken a quantitative immunohistopathological assessment of immune cells expressing the immunoinhibitory T cell immune response cDNA 7 receptor (TIRC7), an emerging immunoinhibitory receptor, in a cohort of 135 CCA patients. TIRC7
Identifiants
pubmed: 34944891
pii: cancers13246272
doi: 10.3390/cancers13246272
pmc: PMC8699724
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 314905040
Organisme : The European Union's Horizon 2020 research and innovation programme under Eurostars
ID : E! 113707 LiverQR
Organisme : German Cancer Aid
ID : 70113922
Références
Genomics. 1999 May 1;57(3):398-406
pubmed: 10329006
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918309
Ann Oncol. 2010 Aug;21(8):1712-1717
pubmed: 20147741
Crit Rev Oncol Hematol. 2016 Apr;100:88-98
pubmed: 26895815
Oncol Lett. 2020 Dec;20(6):300
pubmed: 33101494
Immunity. 1998 Oct;9(4):509-18
pubmed: 9806637
Gastric Cancer. 2016 Jan;19(1):42-52
pubmed: 25424150
Oncol Lett. 2021 Apr;21(4):252
pubmed: 33664816
Blood. 2018 Jan 4;131(1):58-67
pubmed: 29118008
Nat Rev Cancer. 2005 Jan;5(1):65-72
pubmed: 15630416
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
Hum Pathol. 2016 Jan;47(1):78-84
pubmed: 26541326
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Hepatology. 2021 Jan;73 Suppl 1:75-85
pubmed: 32500550
Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5
pubmed: 8857851
Clin Exp Immunol. 2006 Apr;144(1):142-51
pubmed: 16542376
Nat Rev Genet. 2012 Nov;13(11):795-806
pubmed: 23044827
Cell Rep. 2019 Dec 10;29(11):3766
pubmed: 31825850
Transpl Immunol. 2006 Nov;16(3-4):238-44
pubmed: 17138060
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Br J Cancer. 2015 Nov 3;113(9):1343-9
pubmed: 26461054
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Cancer. 2011 May 15;117(10):2192-201
pubmed: 21523733
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
Front Bioeng Biotechnol. 2019 Oct 15;7:270
pubmed: 31681747
Oncol Rep. 2020 Jul;44(1):43-54
pubmed: 32319655
PLoS One. 2008 Feb 13;3(2):e1576
pubmed: 18270567
Am J Transplant. 2004 Apr;4(4):505-14
pubmed: 15023142
J Immunol. 2006 Nov 15;177(10):6833-41
pubmed: 17082597
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Nat Rev Gastroenterol Hepatol. 2011 Aug 02;8(9):512-22
pubmed: 21808282
Diagn Pathol. 2019 May 8;14(1):36
pubmed: 31068195
Acta Oncol. 2020 Jun;59(6):696-704
pubmed: 32193962
J Immunol. 2004 Aug 15;173(4):2342-52
pubmed: 15294947
J Hepatol. 2020 Nov;73(5):1007-1009
pubmed: 32900521
Br J Cancer. 2013 Nov 12;109(10):2665-74
pubmed: 24136146